Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Cash Flow (2023 - 2025)

Compass Therapeutics' Net Cash Flow history spans 3 years, with the latest figure at -$15.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 354.65% year-over-year to -$15.6 million; the TTM value through Dec 2025 reached -$12.8 million, down 166.68%, while the annual FY2025 figure was -$12.8 million, 166.68% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$15.6 million at Compass Therapeutics, down from $23.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $23.4 million in Q3 2025 and bottomed at -$18.2 million in Q2 2025.
  • The 3-year median for Net Cash Flow is -$3.4 million (2024), against an average of -$358583.3.
  • The largest annual shift saw Net Cash Flow surged 198.64% in 2024 before it tumbled 354.65% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$6.2 million in 2023, then skyrocketed by 198.64% to $6.1 million in 2024, then tumbled by 354.65% to -$15.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Net Cash Flow are -$15.6 million (Q4 2025), $23.4 million (Q3 2025), and -$18.2 million (Q2 2025).